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Abstract: New chitosan derivatives modified with (3-carboxypropyl)trimethylammonium chloride
(1) and coupled with (OC-6-44)-diammine(4-carboxypropanoato)dichloridoethanolatoplatinum(IV)
(2), were synthesized and their preliminary biological evaluation carried out in human tumor cells.
Some of these derivatives were also loaded with a chelating ligand (3) that was derived from
bis(quinolin-2-ylmethyl)amine to obtain chitosan-based nanoparticles for an EPR-mediated delivery
of Pt(IV) prodrugs and Re(I) tricarbonyl complexes (4), to explore a multimodal theranostic approach
to cancer. The cytotoxicity of the different chitosan conjugates (C12, C123, and C1234), carrying
different combinations of the Pt(IV) complex, the chelator and the Re(I) complex, was evaluated in the
A2780 human ovarian cancer cell line using the MTT assay. The Pt(IV)-containing nanosystems
showed low to moderate cytotoxic activity (IC50 values in the range 13.5–33.7 µM) and was
comparable to that found for the free Pt(IV) complex (IC50 = 13.7 µM). Therefore, the Pt(IV)-chitosan
conjugation did not enhance the cytotoxic activity of the Pt(IV) prodrug, which certainly reflects
the inefficient cellular uptake of the nanoconjugates. Nevertheless, a clearer view of their potential
for the delivery of anticancer agents requires further in vivo tests because the EPR effect increases
extravasation and retention within the tumor tissue, not necessarily within the tumor cells.
Keywords: theranostics; platinum prodrugs; rhenium complexes; chitosan; drug targeting
and delivery
1. Introduction
In 1978, cisplatin (i.e., (SP-4-2)-diamminedichloridoplatinum(II)) was approved by the Food and
Drug Administration as an anticancer drug. Since then, this simple Pt(II) compound has become one
of the most widely used chemotherapeutic agents. It is best known for curing testicular cancer, but it
is also used in the treatment of a wide range of other cancers, including lung, bladder, cervical, and
ovarian cancers, alone or in combination with other drugs [1–3].
One of the major problems of Pt chemotherapeutic agents is their non-specific toxicity. Such toxic
action to normal cells limits the dose of the anticancer drugs to be administered to patients, which
results in unsatisfactory efficacy. To overcome this obstacle, conjugation of the drugs to suitable carriers
has been studied to provide site-specificity and to increase the drug concentration at the tumor site
(drug targeting and delivery, DTD).
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In general, there are two possibilities of localizing a drug in the proximity of a tumor: the active
and the passive ones. The former is based on coupling the drug with a macro/molecular ligand to target
it to tumor tissues/cells involving specific recognition mechanisms (i.e., antigen-antibody interaction,
peptide-based targeting, DNA, or RNA-based ligands, etc.). On the other hand, passive DTD uses
the characteristic enhanced permeation and retention of the vasculature of the tumor (EPR effect), by
which it is possible to concentrate drug-loaded nanoparticles within the tumor tissue [4]. To date, many
macromolecular drugs based on EPR effect were developed, more of them are in preclinical stages,
and some others are used in clinic, including liposomes, polymers, micelles, and nanoparticles [5].
Recently, the functionalization of nanostructured materials with anticancer Pt-based metallodrugs,
to improve biological activities while decreasing the adverse toxicological effects, has attracted a lot of
attention [6–13].
Whatever the DTD method, the release of the drug at the right moment and at the right position
is crucial. In the case of square-planar Pt(II) drugs, the design of the linker between the metal moiety
and the vector is of great importance. In fact, the spacer should contain a hydrolysable group to
guarantee the release of the active Pt metabolite [14,15]. On the contrary, the use of octahedral Pt(IV)
complexes may overcome some of the synthetic difficulties. Pt(IV) prodrugs are activated by reduction
to their cytotoxic Pt(II) metabolites in the hypoxic (reducing) tumor milieu releasing the two axial
ligands (Scheme 1) [16–18]. For this reason, the axial ligands on Pt(IV) complexes constitute ideal DTD
vectors, since they will be released upon reduction without altering the overall activity of the final
Pt(II) metabolite.
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X = carboxylatos, chloridos, etc., R = alkyl or aryl groups.
The clinical use of cisplatin in combination with other drugs resides in the imita ions of
monotherapies to f lly fight a c mplex disease, such as cancer. To attack cancer multiple fronts, a
multi-target drug may be more successful than a single component. For this reason, by combining
two drugs, the probability of killing the cancer rises. So, a nanoparticle, having multiple sites able
to react with several molecules, may be loaded with both a Pt-based drug and a second “weapon”
(e.g., an organic drug synergistic with Pt, a radioactive isotope, etc.), and the conjugate will (should)
transport and deliver both drugs simultaneously to the final destination.
Alternatively, the second drug may be replaced by an active reporter, to combine therapy
and diag ostics in t e same device, to tre t and image efficacy wit one single tool. Indeed,
the develop ent of novel age ts bining diagnostic and therapeu ic (theranosti ) to ls has emerged
as a new pproach to fight canc r over the last decade [19,20]. Towards this goal, isostructural M(I)
(M = 99mTc or Re) tricarbonyl complexes have useful and unique features: (i) chemical robustness of
the fac-[M(CO)3]+ core; (ii) well-studied coordination chemistry with a variety of chelating ligands
including targeting molecules [21,22]; and, (iii) possible application in the design of metal-based
cancer theranostic agents where Re complexes can be incorporated into a cytotoxic entity that will
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exert a therapeutic effect, while the 99mTc congeners are part of the corresponding imaging tool
for in vivo assessment of tumor accumulation. Furthermore, the Re(I) tricarbonyl complexes have
also been recently explored as photosensitizers for photodynamic therapy (PDT) [23–25]. PDT is
a clinically approved technique used , for instance, for the treatment of certain tumors, which
involves light-induced generation of cytotoxic singlet oxygen (1O2) from endogenous 3O2 and/or
other reactive oxygen species (ROS), mediated by a photosensitizer. When compared with other
conventional anticancer treatments, PDT has many advantages, namely spatial and temporal control
and the possibility of repeated doses [19,26]. In particular, Re(I) tricarbonyl complexes with ligands
derived from bis(quinolin-2-ylmethyl)amine can act as efficient photosensitizers and are endowed with
luminescence properties that might also allow for the visualization of their intracellular trafficking by
fluorescence microscopy [24,25].
In this work, it is reported the preparation and preliminary evaluation
of the biological properties of low viscosity chitosan from shrimp shell,
modified with (3-carboxypropyl)trimethylammonium chloride (1), coupled with
(OC-6-44)-diammine(4-carboxypropanoato)dichloridoethanolatoplatinum(IV) (2) and loaded
with the chelating ligand 3, as derived from bis(quinolin-2-ylmethyl)amine for possible coordination
of the Re(I) tricarbonyl moiety (Scheme 2). The idea was to use chitosan–based nanoparticles for
an EPR-mediated accumulation of Pt(IV) prodrugs and Re(I) tricarbonyl complexes, to explore a
multimodal theranostic approach to cancer. As a proof of principle, the coordination capability of the
functionalized chitosan towards the fac-[Re(CO)3]+ was also evaluated and allowed for the synthesis
of the final nanoconjugate C1234, as depicted in Scheme 2. To have an insight on the influence of the
different payloads in the biological performance of the nanoconjugates, their cytotoxicity and cellular
uptake were evaluated in the A2780 human ovarian cancer cell line.
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2. Results and Discussion
2.1. Synthesis and Characterization of the Conjugates
Chitosan is a linear polysaccharide containing randomly distributed β-(1-4)-linked D-glucosamine
and N-acetyl-D-glucosamine (Scheme 2). It is a nontoxic, biodegradable, and biocompatible [27]
derivative of chitin (the second most abundant polysaccharide in nature after cellulose and one of
the main components of the exoskeleton of crustaceans and insects [28]), and it is obtained by partial
deacetylation of chitin amines with alkaline hydrolysis. The number of N-acetyl groups is expressed
as molar percentage and is defined as acetylation degree (AD). When AD is lower than 60%, chitin is
considered chitosan. Another characteristic that allows the evaluation the nature of the polysaccharide
is the solubility in aqueous solution of organic acids (such as acetic acid), which is verified for AD
lower than 50–60% [28]. Depending on acetylation degree and pH (pKa of amino groups from 6.2 to
7.0), chitosan is a polycation with variable charge density [29]: it is protonated (and soluble) in acids
with pKa < 6.2, whereas it cannot be dissolved in water, alkaline, or physiological aqueous solutions
and organic solvents [30].
The titration of chitosan to quantify the free amine functionalities (5.16 mmol –NH2 groups g−1
chitosan, see experimental part for details) showed it was almost insoluble at physiological pH.
This feature made necessary to introduce ammonium groups into this polysaccharide. In fact,
to improve the water solubility of chitosan, it is possible to modify it with molecules, such as PEG or
ammonium derivatives [29,31–33]. In particular, the quaternarization allows chitosan to be soluble
in water, regardless of pH, only if the quaternarization degree represents at least the 25% of the
total available amino groups [34]. For this purpose, (3-carboxypropyl)trimethylammonium chloride
was activated with the coupling agent N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uronium
hexafluorophosphate (HBTU, belonging to the uronium salt family), in the presence of the tertiary
amine N,N-diisopropylethylamine (DIPEA), and directly mixed with the nucleophilic species, i.e., the
–NH2 groups of chitosan (conjugate C1, about 30% of quaternization degree. See experimental).
To carry out the reaction between the carboxylic groups of Pt(IV) complex 2 and the amine
functionalities of chitosan, the complex was initially activated in the form of succinimidyl ester with
N-hydroxysuccinimide (NHS) and the common coupling agent N,N′-dicyclohexylcarbodiimide (DCC).
The resulting active intermediate reacted with ammonium-modified chitosan C1 to give the Pt-loaded
conjugate C12. Different amounts of Pt(IV) complex and different reaction times were employed
in this study (see Appendix A: Tables A1 and A2) in order to select the best compromise in terms
of reaction time and amount/cost of Pt(IV) prodrug. As detailed in the experimental section, the
loading conditions produced a C12 conjugate containing 35.2 ± 6.0 µmol Pt g−1 chitosan (mean of
three independent experiments). These were chosen to maximize the Pt loading in relatively short
reaction times, and to limit the amount of 2 that was used in the syntheses.
Prodrug 2 was chosen based on previous studies where it was loaded on amino-functionalized
nonporous silica nanoparticles resulting in conjugates with high cellular uptake and good
antitumor activity [35,36]. Moreover, the presence of only one axial carboxylate functionality
prevents the formation of cross-links between amino groups of different C1 molecules decreasing
the size of the nanoparticles [36]. Complex 2 is stable in HEPES buffer (HEPES =
4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid; pH = 7.5), but it can be reduced to cisplatin by
bioreductants such as ascorbic acid (AA), with pseudo first-order initial rate constant k = 1.2 × 10−3 s−1
(t1/2 = 9.4 h) and it was therefore released by the nanoparticles in the presence of AA, accordingly.
To verify the behaviour of 2 loaded onto chitosan, conjugate C12 was challenged with HEPES buffer
(2 mM, pH = 7.5), with and without AA (see experimental section). In HEPES, the release of platinum
was 2% over 48 h, whereas in the presence of AA, it reaches 48% in 8 h and 75% in 24 h. During the
tests of antiproliferative activity, almost the whole Pt loading of chitosan may be released. In any case,
it has been demonstrated that for such Pt(IV) prodrugs, the cytosolic content is able to completely and
quickly reduce them to their Pt(II) active metabolite (in this case, cisplatin) [18,37,38].
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After loading the Pt(IV) complex, the conjugate C12 was further decorated with the
tridentate ligand 3 using the above said coupling procedure with HBTU and DIPEA. Finally,
the resulting conjugate C123 was used to coordinate the fac-[Re(CO)3]+ core, by the reaction with
fac-[ReIBr3(CO)3][NEt4]2 with the known procedure at reflux in methanol [39,40], to give the conjugate
C1234. The whole synthetic pathway is reported in Scheme 3.
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Scheme 3. Synthetic pathway from chitosan C to conjugate C1234. HBTU = N,N,N′,N′-tetramethyl-
O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate, DIPEA = N,N-diisopropylethylamine,
NHS = N-hydroxysuccinimide, DCC = N,N′-dicyclohexylcarbodiimide.
After each reaction step, the size and the ζ-potential of the conjugates were checked (Table 1).
Moreover, the Pt and Re content was determined with inductively coupled plasma-optical emission
(ICP-OES) technique after mineralization of the samples: 34.8 ± 9.8 µmol Pt g−1 chitosan;
65.3 ± 12.1 mmol Re g−1 chitosan (mean of three independent syntheses). Finally, the IR spectrum
of conjugate C1234 showed two ν(C≡O) bands at 1895 and 2017 cm−1, which are typical of the
fac-[Re(CO)3]+ core; these bands appear at frequencies that are similar to those observed for the Re(I)
tricarbonyl complex with ligand 3 (1902 and 2016 cm−1, respectively).
Table 1. ζ-potential and dynamic light scattering (DLS) diameter for chitosan derivatives.
Compound ζ-potential (mV) DLS Diameter (nm)
C1 41.5 ± 3.1 180 ± 10
C12 37.5 ± 0.6 215 ± 12
C123 45.9 ± 1.1 298 ± 21
C1234 39.0 ± 2.4 300 ± 24
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TEM (Transmission Electron Microscopy) analyses indicated that the nanoparticles are spherically
shaped, with a diameter size averaging 35 nm, as exemplified for C123 in Figure 1. The difference in
the size of the conjugates between DLS (giving the hydrodynamic diameter by dispersing particles in
aqueous phase) and TEM (giving the diameter of dried samples) analyses may be due to hydration
and swelling of the samples in aqueous media, as well as to some degree of aggregation.
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2.2. Antiproliferative Activity and Cellular
To assess the cytotoxic activity of the different chitosan conjugates carrying the
Pt(IV) prodrug, cancer cells were incubated for 48 h with increasing concentrations of
the conjugates C12, C123, and C1234, and the cellular viability was evaluated by the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. This study was run in
parallel for the C1 chitosan platform and free Pt-complex 2. The inhibition of growth (%) was calculated
and the IC50 values were determined in mg·mL−1 for chitosan-containing particles, and in µM
Pt concentrations for Pt-conjugates (Table 2). The ammonium-modified chitosan C1 showed the
lowest cytotoxicity with an IC50 value of 2.06 ± 0.83 mg·mL−1. The monosuccinato Pt-complex 2,
although containing a free carboxylic group that could impart a low lipophilicity and reduce the
cellular uptake, showed an antiproliferative activity of the same order of cisplatin (IC50: 13.7 ± 3.0
and 20.7 ± 5.6 µM [41] for 2 and cisplatin, respectively). The linkage of the Pt(IV)-complex 2 to
chitosan caused a slight increase of the cytotoxic activity of the nanosystems: the IC50 values were
reduced from 2.06 (C1) to 1.34 mg·mL−1 (C12), although still being lower than that of complex 2
(33.7 vs. 13.7 µM, for C12 and 2, respectively). By contrast, the incorporation of the tridentate ligand
3 led to a chitosan-conjugate (C123) presenting an IC50 value (13.5 µM) similar to that found for
the free Pt(IV) complex. These data are in clear contrast with the nanomolar IC50 values obtained
for Pt(IV)-silica nanoparticles, carrying the same Pt(IV) prodrug [35,36]. Hence, it seems that the
Pt(IV)-chitosan conjugation do not result in an improvement of the cytotoxic activity, namely when
compared with cisplatin.
Table 2. Antiproliferative activity (IC50) and accumulation ratio (AR) on A2780 cells.
Compound or Conjugate IC50 (mg·mL−1) 1 IC50 (µM) 2 Pt AR Re AR
cisplatin - 20.7 ± 5.6 - -
2 - 13.7 ± 3.0 0.385 ± 0.091 3
C1 2.06 ± 0.83 - - -
C12 1.34 ± 0.35 33.7 ± 8.9 3.56 ± 0.19 -
C123 0.43 ± 0.06 13.5 ± 2.0 - -
C1234 0.65 ± 0.29 26.0 ± 11.8 2.31 ± 0.12 3.00 ± 0.87
IC50 values are expressed as: 1 mg·mL−1 of conjugate or 2 µM of Pt; 3 from refs. [35,36].
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In the attempt to explain the poor antiproliferative activity of the conjugates, their cellular uptake
was measured on A2780 human ovarian cancer cells. Cells were treated for 4 h with an external
concentration of Pt between 6 and 8 µM, as checked by ICP-MS. The results of Pt and Re cellular
accumulation were expressed in terms of the dimensionless accumulation ratio AR, i.e., the ratio
between intra- and extra-cellular metal concentration. Conjugates C12 and C1234 showed AR values
for both Pt and Re of about 3 (Table 2). These data seem to be quite low for metal drugs carried by
macromolecular/nanoparticular vectors.
The scarce antiproliferative activity of the conjugates may have, therefore, its explanation in their
corresponding low cellular accumulation. Generally, positively charged nanoparticles show higher
uptake through endocytosis pathways than negatively charged counterparts, as observed for other
Pt-loaded nanovectors of similar size and ζ-potential. In fact, spherical nonporous silica nanoparticles
(NSNP) with an external shell containing primary amino groups were used as delivery systems for
different Pt(IV) complex. The conjugates Pt(IV)-NSNP exhibited much better antiproliferative activity
on the Pt-sensitive ovarian A2780 cell line than parent cisplatin and free complexes, due to their
more efficient cellular uptake (in all cases AR > 30) [35,36]. On the contrary, phenanthriplatin (i.e.,
(SP-4-3)-diamminechlorido(phenanthridine)platinum(II) nitrate) loaded on negatively charged dextran
sulfate, a polysaccharide not very different from chitosan, resulted in slightly less active than free
phenanthriplatin. Also, in this case, the slightly lower AR (3.03 for conjugate vs. 4.81 for free complex)
may justify this behavior [42]. Chitosan proved not to be an efficient carrier for the studied metal drugs:
it increases the AR of the free Pt complex but it does not reach high levels. Very recently, mesoporous
SNP (MSNP) functionalized with amino groups and then with hyaluronic acid (HA) or chitosan (C),
showed very significant differences in terms of cellular uptake: MSNP-NH2 and MSNP-HA were
distributed in the cytoplasm of 3T3 mouse fibroblast cells, whereas MSNP-C were not able to penetrate
the cells [43]. This result is in line with the data obtained in the current study.
3. Materials and Methods
3.1. General Procedures
K2[PtCl4] (Alfa Aesar-Thermo Fisher, Karlsruhe, Germany) and all other chemicals (Alfa
Aesar-Thermo Fisher, Karlsruhe, Germany, and Sigma Aldrich Italia, Milan, Italy) were used without
further purification. (OC-6-44)-diammine(4-carboxypropanoato)dichloridoethanolatoplatinum(IV)
(2) was prepared and activated in its succinimidyl ester form, according to previously published
procedure [35,36]. The ligand 5-[bis(quinolin-2-ylmethyl)amino]pentanoic acid (3) was synthesized,
as described elsewhere [44]. Conductometric titrations were performed with a AMEL 160 conductivity
meter and potentiometric titrations were performed with an AMEL 334-B pH meter (AMEL, Milan,
Italy), both at 25.0 ± 0.1 ◦C by using a thermostatic circulating bath to keep the temperature of the
sample constant. For the mineralization of the conjugates, 4–5 mg of product were mineralized by
means of an acid digestion in 800 µL of 70% w/w HNO3 using an ultrasonic bath at 60 ◦C for 1 h.
The samples were then diluted with 1% v/v HNO3. The Pt and Re content of the conjugates was
quantified by means of inductively coupled plasma-optical emission spectrometry (ICP-OES), using a
Spectro Genesis ICP-OES spectrometer (Spectro Analytical Instruments, Kleve, Germany) equipped
with a crossflow nebulizer. In order to quantify the metal concentrations, the 299.797 nm and the
221.426 nm lines were used for Pt and Re, respectively. Platinum and rhenium standard stock solutions
of 1000 mg·L−1 were diluted in 1% v/v nitric acid to prepare calibration standards. Particle size
and ζ-potential were measured by dynamic light scattering (DLS) at 25 ◦C, at a fixed ionic strength,
to compare the characteristics of the different particle samples, with a Malvern Zetasizer Nano ZS
(Malvern Instruments Ltd., Malvern, UK) at a fixed scattering angle of 173◦, using a He–Ne laser and
DLS software for Windows (version 6.11, Malvern, UK). IR spectra (dry KBr plates, 2 cm−1 resolution)
were recorded on a Bruker FTIR Equinox 55 spectrometer (Bruker Optik, Ettlingen, Germany) in the
range 4000–400 cm−1. Transmission electron microscopy (TEM) images were obtained on a JEOL
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1400 (JEOL Ltd., Tokyo, Japan) instrument. TEM samples were prepared by placing 5 µL of gold
nanoparticle solution on the 300 mesh carbon coated copper grid. Excess solution was removed
carefully and the grid was allowed to dry for an additional five minutes. Pt and Re cellular content
was measured by inductively coupled plasma-mass spectrometry (ICP-MS, Thermo Optek X Series
2, Thermo Scientific, Waltham, MA, USA). Instrumental settings were optimized in order to yield
maximum sensitivity for platinum. For quantitative determination, the most abundant isotopes of
platinum, rhenium, and indium (used as internal standard) were measured at m/z 195, 187 and
115, respectively.
3.2. Titrations: Deacetylation Degree of Chitosan
The quantification of the deacetylation degree (DD) of chitosan (i.e., of its amino groups) was
carried with a conductometric titration [30]. In particular, 93.3 mg of chitosan were dissolved in 20 mL
of 0.0540 M HCl and then the solution was titrated with 0.158 M NaOH, measuring the conductivity of
the solution (mS·cm−1) after each titrant addition. The data pointed out 5.16 mmol –NH2 groups g−1
of chitosan, with an acetylation degree (AD) of 16.9 mol %. The corresponding potentiometric titration
allowed for finding the pH ranges of solubility of chitosan: up to about pH 4 almost all of the amino
functionalities are still protonated, whereas going on with the deprotonation (from pH around 4.5–5)
chitosan started to precipitate and at neutral pH it was completely precipitated.
3.3. Synthesis of the Chitosan Modified with (3-Carboxypropyl)trimethylammonium Chloride (C1)
A mixture of (3-carboxypropyl)trimethylammonium chloride (1, 256 mg, 1.41 mmol), HBTU
(803 mg, 2.12 mmol), and DIPEA (738 µL, 4.24 mmol) in 4 mL of anhydrous DMF was magnetically
stirred for 30 minutes. Then, the protonated chitosan (228 mg, 1.18 mmol amine) and DIPEA
(615 µL, 3.53 mmol) were added and the resulting mixture was stirred at room temperature for
24 h. The solvent was removed under reduced pressure and the product was dialyzed (dialysis tubing
cellulose membrane with 14 kDa molecular weight cut-off) in ultrapure water for 2 d. After dialysis,
the chitosan derivative was completely dissolved in water; then the sample was frozen with liquid
nitrogen and lyophilized to get a beige powder. The amount of the ammonium derivative loaded
on chitosan was quantified, as described above in Section 3.2. In particular, 21.0 mg of the sample
were dissolved in 10 mL of 0.054 M HCl and titrated with 0.2 M NaOH by using a conductivity meter.
The results showed that 29.5% of chitosan amino groups (1.52 mmol·g−1 of chitosan) was coupled
with the ammonium derivative.
3.4. Loading of the Pt(IV) Complexes on Chitosan (C12)
To a suspension of C1 in anhydrous DMF (228 mg of chitosan in 4 mL) prepared, as described
in Section 3.3, activated complex 2 was added and the mixture was stirred. Different amounts of
Pt(IV) complex and different reaction times were employed (see Appendix A: Tables A1 and A2) in
order to select the best compromise in terms of reaction time and cost. After the established time,
a small aliquot of the suspensions was processed: DMF was removed under reduced pressure and the
conjugate was dialyzed in ultrapure water for 2 d, obtaining a completely water-soluble product. Then,
few mg of the conjugate were frozen by means of liquid nitrogen, lyophilized, mineralized, diluted
with 1% v/v HNO3, and analyzed by means of ICP-OES to quantify the coordinated Pt. The use of
13.2 mg of activated 2 (i.e., 0.0236 mmol, corresponding to 2% respect to the total amino groups) and
4 h reaction time was chosen as standard loading conditions, producing conjugate C12 containing
35.2 ± 6.0 µmol Pt g−1 chitosan (mean of three independent experiments).
3.5. Coupling of the Modified Chitosan Conjugate C12 with the Ligand
5-[bis(Quinolin-2-ylmethyl)amino]pentanoic Acid, 3 (Conjugate C123)
A solution of the tridentate ligand 3 (9.1 mg, 0.0228 mmol), HBTU (13.0 mg, 0.0342 mmol) and
DIPEA (7.94 µL, 0.0456 mmol) in anhydrous DMF (1 mL) was stirred for 30 minutes and then it was
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added to the solution of C12 in DMF (prepared as described in Section 3.4). The reaction was carried
out at room temperature for 24 h. Then, DMF was removed under reduced pressure and the sample
was recovered with ultrapure water, causing the precipitation of a dark brown powder (unreacted
ligand), removed by extraction with dichloromethane. The aqueous phase (about 20 mL) was then
dialyzed (MW cut-off membrane of 14 kDa) in ultrapure water for 2 d.
3.6. Chelation Reaction of Conjugate C123 with the Re(I) Complex (C1234)
Fac-[ReBr3(CO)3][NEt4]2 (17.6 mg, 0.0228 mmol) was added to 10 mL of the dialyzed water
solution of C123 (see Section 3.5) and the reaction was let to proceed at 70 ◦C overnight. The solution
was then dialyzed in ultrapure water for 2 d to separate the unreacted Re(I) tricarbonyl precursor
from conjugate C1234. To determine the Pt and Re payloads of C1234, an aliquot of the final solution
was frozen by liquid nitrogen and then lyophilized. The recovered C1234 (4–5 mg) was mineralized
by using the previously described method, diluted with 1% v/v HNO3 and analyzed by means of
ICP-OES to quantify the Pt and Re contents. The procedure was repeated at least three times. The Pt
loading was 34.8 ± 9.8 µmol Pt g−1 chitosan (0.68 ± 0.19% of the total amino groups), whereas the Re
loading was 65.3 ± 12.1 µmol Re g−1 chitosan (1.27 ± 0.24% of the total amino groups). IR (KBr): 1895
and 2017 cm−1.
3.7. Solution Behaviour
Stability in pseudo-physiological conditions and reduction with ascorbic acid of C12 (0.5 mM final
Pt concentration) were studied in 2 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES)
buffer (pH = 7.5), with or without 5 mM ascorbic acid at different time intervals over 48 h at 25 ◦C.
In particular, the spontaneous Pt leaking (i.e., in the absence of any reducing agents) was evaluated by
considering conjugate C12. In particular, a concentrated HEPES buffer solution was added to an aliquot
of the final aqueous solution of C12 (see Section 3.4) to obtain a final 2 mM HEPES concentration (pH
7.5); the resulting solution was dialyzed against aqueous 2 mM HEPES (without refreshing the solution;
membrane Molecular Weight Cut-off, MWCO = 14,000 u) for 48 h at 25 ◦C, in order to verify the
spontaneous Pt release. After the fixed time, the whole dialyzed solution was lyophilized, mineralized,
diluted with a known volume of 1% v/v HNO3, and analyzed by ICP-MS. The residual Pt content
was expressed as percent of the initial amount. A similar procedure was performed in the presence of
ascorbic acid (10-fold molar excess respect to the platinum content), employing independent samples
that were analyzed after different time intervals up to 48 h. In particular, ascorbic acid was added to
different samples of the C12 HEPES solution, which were stirred for the established time. Each solution
was then dialyzed, refreshing the dialysis medium every 15 minutes to avoid a further detachment due
to the presence of the reducing agent. Finally, the dialyzed solutions were lyophilized, mineralized,
diluted with 1% v/v HNO3, and analyzed by ICP-MS. Also, in this case, the residual Pt content was
expressed as percent of the initial amount.
3.8. Antiproliferative Activity
The antiproliferative activity of the conjugates under investigation was assessed by the evaluation
of their effects on cellular proliferation using the [1-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium]
(MTT) assay. Ovarian cancer A2780 cells were seeded in 96-well culture plates at a density of
2 × 104 cells per well, and were left to adhere overnight at 37 ◦C. Cells were then incubated with
the conjugates at different dilutions (0–50 µM of Pt content) during 48 h at 37 ◦C and 5% CO2.
After incubation, the conjugates were removed and cells were washed with phosphate buffered
saline (PBS, 200 µL). The cellular viability was assessed by incubating cells with MTT (200 µL of
0.5 mg·mL−1 solution in Modified Eagle’s Medium without phenol red) during 3h at 37 ◦C. The MTT
solution was removed and the insoluble and blue formazan crystals that formed were dissolved
and homogenized with DMSO (200 µL per well). The absorbance of this colored (purple) solution
was quantified by measuring the absorbance at 570 nm, using a plate spectrophotometer (Power
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Wave Xs; Bio-Tek, Winooski, VT, USA). A blank solution was prepared with DMSO alone (200 µL per
well). Each test was performed with at least six replicates. Inhibition of growth (%) was calculated
by correlation with a control incubated without compound. IC50 values (i.e., concentration which
reduces the growth by 50%) were determined using the Graph Pad Prism software and expressed in
micromolar concentrations.
3.9. Cellular Uptake
Ovarian cancer A2780 cells, seeded in 10 mm Petri dishes, were treated with the conjugates under
investigation ([Pt] between 6 and 8 µM) for 4 h in complete medium. At time zero, 100 µL of the
medium was taken out from each sample to check the extracellular Pt concentration. At the end of
the exposure, cells were washed three times with PBS, detached from the Petri dishes with 0.05%
Trypsin 1× and 2% EDTA (HyClone, Thermo Fisher, Karlsruhe, Germany), and harvested in fresh
complete medium. An automatic cell counting device (Countess®, Life Technologies, Thermo Fisher,
Karlsruhe, Germany) was used to measure the number and mean diameter of the cells. To analyze
the cellular Pt and Re accumulation, the cells were transferred into a borosilicate glass tube and
centrifuged at 1100 rpm for 5 min at room temperature. The main part of the supernatant was removed
by aspiration, leaving about 200 µL to limit the cellular loss. Cellular pellets were stored at −20 ◦C
until mineralization. Once defrosted, 70% w/w HNO3 (350 µL) was added to each sample, which was
left 1 h at 60 ◦C in an ultrasonic bath. Then, they were diluted with 1% v/v HNO3 to a final 3% v/v
acid concentration and were analyzed by means of ICP-MS to quantify the Pt and Re concentration.
The cellular metal contents after drug treatment, normalized upon the cell number, was expressed as
ng metal per 106 cells. From the measured mean cell diameter, the cellular volume was calculated
for each sample to express cellular metal content in terms of molar concentration. Finally, the ratio
between the intra- and extra-cellular (i.e., in the culture medium) concentrations was defined as the
accumulation ratio (AR) [45,46].
4. Conclusions
In this work, the Pt(IV) complex (OC-6-44)-diammine(4-carboxypropanoato)dichloridoethanolatop
latinum(IV) and the Re(I) tricarbonyl complex of 5-[bis(quinolin-2-ylmethyl)amino]pentanoic acid,
were conjugated to the polysaccharide carrier chitosan. DLS and zeta-potential measurements
proved that the different nanoconjugates display zeta potential and hydrodynamic size values
ranging between 37.5–45.9 mV and 215–300 nm. In particular, C1234 shares similar physico-chemical
properties with the chitosan nanoconjugate (C12), carrying only the Pt(IV) prodrug. Therefore,
the presence of the Re(I) probe did not disturb the physico-chemical properties of the chitosan
nanoplatform that was thought originally as a carrier to deliver the Pt(IV) prodrug. Moreover,
the presence of the Re(I) tricarbonyl complex also did not compromise the albeit small cytotoxic
activity of the Pt(IV)-containing chitosan nanosystems. Most importantly, these nanoplatforms can
be equipped with imaging/diagnostic properties, namely by replacing the fac-[Re(CO)3]+ by the
congener fac-[99mTc(CO)3]+ core.
The lower in vitro antiproliferative activity of C1234 with respect to free 2 is due to the inefficient
cellular uptake, as demonstrated by the accumulation ratio measurements. However, EPR effect
increases extravasation and retention within the tumor tissue, but not necessarily within the tumor
cells. For this reason, nanoparticles can be loaded with anticancer agents that accumulate and release
their payload in the tumor environment, in the actual case, through activation by reduction. Therefore,
the true active metabolite that will enter the cells may be the reduced Pt(II) active metabolite. Further
in vivo tests will be necessary to appreciate any EPR effect for the conjugates to confirm the potential
of the designed chitosan derivatives for the transport of anticancer agents.
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Appendix
Table A1. Pt loadings on chitosan at different reaction times with a fixed amount of 2 (0.0236 mmol
i.e., theoretical maximum % Pt loading = 2) (mean of three independent experiments). The results are
expressed as percentage respect to the amino groups density (5.16 mmol·g−1 chitosan).
Conjugate Reaction Time Experimental % Pt Loading µmol Pt g−1 Chitosan
C12a 2 h 0.78 ± 0.02 40.0 ± 0.9
C12b 4 h 0.68 ± 0.12 35.2 ± 6.0
C12c 6 h 0.86 ± 0.03 44.1 ± 1.5
C12d 8 h 0.61 ± 0.08 31.4 ± 3.9
C12e 24 h 0.99 ± 0.22 51.3 ± 11.2
Table A2. Pt loadings on chitosan at fixed reaction time (4 h) but by using different amounts of activated
complex 2 (mean of three independent experiments). The results are expressed as percentage respect to
the amino groups density (5.16 mmol·g−1 chitosan).
Conjugate Theoretical Maximum % Pt Loading Experimental % Pt Loading µmol Pt g−1 Chitosan
C12f 1 0.45 ± 0.03 23.2 ± 1.5
C12b 2 0.68 ± 0.12 35.2 ± 6.0
C12g 5 1.38 ± 0.12 71.0 ± 6.2
C12h 10 2.63 ± 0.05 135.0 ± 0.3
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